Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?
Hims & Hers Health (HIMS) is back in focus after fresh product news, with Hers Hair now rolling out in…
28,172$
0,37%
Echtzeit-Aktienkurs Hims & Hers Health Inc.
Bid:
Ask:
Nachrichten zur Hims & Hers Health Inc. Aktie
Is Peptide Compounding Review Altering The Investment Case For Hims Shares (HIMS)?
Hims & Hers Health has broadened its telehealth footprint with Hers Hair launching in the UK and the Hers platform…
Peptide Rule Change Could Matter For Hims Shares (HIMS)
Hims & Hers Health recently prepared for potential U.S. regulatory changes on peptide compounding by acquiring a California peptide facility…
Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch
Hims & Hers Health has been a dramatic ride for shareholders over the past few years, yet recent share price…
Hims & Hers Health, Inc. (HIMS) Stock Forecasts
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage…
Hims & Hers Health Inc (HIMS) Stock Down 4.5% -- Now Undervalued? GF Score: 75/100
On October 16, 2026, Hims & Hers Health Inc (HIMS) shares fell 4.5% today, closing at $28.07. The stock has…
What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean?
Hims & Hers Health (NYSE:HIMS) announced the launch of Hers personalised hair loss and wellness care in the UK in…
Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline
/PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit…
How Is Hims & Hers Health, Inc. (NYSE:HIMS) Reshaping Its Business?
Hims & Hers Health, Inc. (NYSE:HIMS) reported strong revenue growth from international expansion while margins and earnings came under pressure.…
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the…
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Hims & Hers (HIMS) urges investors to seek recovery for alleged securities fraud violations – lead…
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…
Hims & Hers Health (HIMS) Shares Rise 6% on Interim Peptide Access Policy News
On October 15, 2026, Hims & Hers Health Inc (NYSE: HIMS) saw its stock price increase by 6% following reports…
Hims & Hers Health rises as HHS moves ahead with plan for compounding peptides
Hims & Hers stock jumps as HHS reviews policy letting compounding pharmacies make peptides like BPC-157. Read more here.…
Hims & Hers chief legal officer sells $100,576 in stock
Hims & Hers chief legal officer sells $100,576 in stock…
Hims & Hers chief legal officer sells $100,576 in stock
Hims & Hers chief legal officer sells $100,576 in stock…
Regencell Bioscience RGC Stock and Hims Attempt Bullish Breakout as Healthcare Stocks Revive
Regencell Bioscience shares surged 35% above $11 before retreating below $10, while Hims & Hers gained 5% as both stocks…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims…
Tim Doyle believed Eucalyptus could hit $10 billion. Heres why he sold it for a fifth of that
Eucalyptus sold to Hims & Hers for $1.6 billion earlier this year. Co-founder Tim Doyle explains the rationale behind the…